GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Herantis Pharma PLC (OHEL:HRTIS) » Definitions » EV-to-FCF

Herantis Pharma (OHEL:HRTIS) EV-to-FCF : -5.39 (As of May. 30, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Herantis Pharma EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Herantis Pharma's Enterprise Value is €25.00 Mil. Herantis Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-4.64 Mil. Therefore, Herantis Pharma's EV-to-FCF for today is -5.39.

The historical rank and industry rank for Herantis Pharma's EV-to-FCF or its related term are showing as below:

OHEL:HRTIS' s EV-to-FCF Range Over the Past 10 Years
Min: -15.19   Med: -7.39   Max: -3.58
Current: -4.78

During the past 13 years, the highest EV-to-FCF of Herantis Pharma was -3.58. The lowest was -15.19. And the median was -7.39.

OHEL:HRTIS's EV-to-FCF is ranked worse than
100% of 372 companies
in the Biotechnology industry
Industry Median: 8.455 vs OHEL:HRTIS: -4.78

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-30), Herantis Pharma's stock price is €1.56. Herantis Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.007. Therefore, Herantis Pharma's PE Ratio for today is At Loss.


Herantis Pharma EV-to-FCF Historical Data

The historical data trend for Herantis Pharma's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Herantis Pharma EV-to-FCF Chart

Herantis Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.73 -4.02 -2.73 -2.96 -5.46

Herantis Pharma Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.73 - -2.96 - -5.46

Competitive Comparison of Herantis Pharma's EV-to-FCF

For the Biotechnology subindustry, Herantis Pharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Herantis Pharma's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Herantis Pharma's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Herantis Pharma's EV-to-FCF falls into.



Herantis Pharma EV-to-FCF Calculation

Herantis Pharma's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=24.997/-4.636
=-5.39

Herantis Pharma's current Enterprise Value is €25.00 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Herantis Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-4.64 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Herantis Pharma  (OHEL:HRTIS) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Herantis Pharma's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.56/-0.007
=At Loss

Herantis Pharma's share price for today is €1.56.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Herantis Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.007.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Herantis Pharma EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Herantis Pharma's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Herantis Pharma (OHEL:HRTIS) Business Description

Traded in Other Exchanges
N/A
Address
Bertel Jungin Aukio 1, Espoo, FIN, 02600
Herantis Pharma PLC is a biotech company developing disease-modifying therapies for Parkinson's disease. The company's current development program focuses solely on HER-096, which is a peptidomimetic molecule designed to retain the biological activity of the neuroprotective CDNF protein.

Herantis Pharma (OHEL:HRTIS) Headlines

No Headlines